In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates

David A. Johnson, John L. Zimmermann, Bennet C. Laguzza, John Eble

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol. Treatments of xenograft-bearing mice with free drug, free antibody, or a mixture of the two, were unsuccessful at achieving suppression without associated toxicity, using otherwise identical protocols. A Vinca conjugate with a related squamous carcinoma reactive monoclonal antibody, PF1/B, was shown to have similar tumor suppressive activity. In a dual immunoconjugate therapy protocol, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD had additive antitumor effects which were consistent with their complementary tumor reactivity.

Original languageEnglish
Pages (from-to)241-245
Number of pages5
JournalCancer Immunology Immunotherapy
Volume27
Issue number3
DOIs
StatePublished - Oct 1988

Fingerprint

Vinca
Immunoconjugates
Squamous Cell Carcinoma
Monoclonal Antibodies
Heterografts
Neoplasms
Vinblastine
Nude Mice
Antibodies
Pharmaceutical Preparations
4-desacetylvinblastine 3-carboxyhydrazide monoclonal antibody conjugates
4-desacetylvinblastine hydrazide
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates. / Johnson, David A.; Zimmermann, John L.; Laguzza, Bennet C.; Eble, John.

In: Cancer Immunology Immunotherapy, Vol. 27, No. 3, 10.1988, p. 241-245.

Research output: Contribution to journalArticle

Johnson, David A. ; Zimmermann, John L. ; Laguzza, Bennet C. ; Eble, John. / In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates. In: Cancer Immunology Immunotherapy. 1988 ; Vol. 27, No. 3. pp. 241-245.
@article{6eb735e0c57c4e0bae8e439f20b345cc,
title = "In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates",
abstract = "An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol. Treatments of xenograft-bearing mice with free drug, free antibody, or a mixture of the two, were unsuccessful at achieving suppression without associated toxicity, using otherwise identical protocols. A Vinca conjugate with a related squamous carcinoma reactive monoclonal antibody, PF1/B, was shown to have similar tumor suppressive activity. In a dual immunoconjugate therapy protocol, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD had additive antitumor effects which were consistent with their complementary tumor reactivity.",
author = "Johnson, {David A.} and Zimmermann, {John L.} and Laguzza, {Bennet C.} and John Eble",
year = "1988",
month = "10",
doi = "10.1007/BF00205446",
language = "English",
volume = "27",
pages = "241--245",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates

AU - Johnson, David A.

AU - Zimmermann, John L.

AU - Laguzza, Bennet C.

AU - Eble, John

PY - 1988/10

Y1 - 1988/10

N2 - An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol. Treatments of xenograft-bearing mice with free drug, free antibody, or a mixture of the two, were unsuccessful at achieving suppression without associated toxicity, using otherwise identical protocols. A Vinca conjugate with a related squamous carcinoma reactive monoclonal antibody, PF1/B, was shown to have similar tumor suppressive activity. In a dual immunoconjugate therapy protocol, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD had additive antitumor effects which were consistent with their complementary tumor reactivity.

AB - An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol. Treatments of xenograft-bearing mice with free drug, free antibody, or a mixture of the two, were unsuccessful at achieving suppression without associated toxicity, using otherwise identical protocols. A Vinca conjugate with a related squamous carcinoma reactive monoclonal antibody, PF1/B, was shown to have similar tumor suppressive activity. In a dual immunoconjugate therapy protocol, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD had additive antitumor effects which were consistent with their complementary tumor reactivity.

UR - http://www.scopus.com/inward/record.url?scp=0023777677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023777677&partnerID=8YFLogxK

U2 - 10.1007/BF00205446

DO - 10.1007/BF00205446

M3 - Article

VL - 27

SP - 241

EP - 245

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 3

ER -